Cellares
United States · Biotech · Healthtech
Cellares manufactures cell therapies for drug developers using automated production and quality-control systems deployed through its Smart Factory network.
From process development to commercial supply
Cellares provides development and manufacturing services for cell-therapy companies. Its Cell Shuttle platform automates production steps, while Cell Q supports in-process and release quality control. Drug developers use the integrated service to transfer and scale manufacturing processes as treatments progress through clinical development toward commercial supply.
A network of manufacturing sites
The company operates a commercial-scale Smart Factory in Bridgewater, New Jersey, and is developing additional capacity in Europe and Japan. Its platform supports several cell-therapy modalities, including CAR T, TCR-T and progenitor T cells. Customers and partners include Bristol Myers Squibb and Cabaletta Bio.
Funding history
2 rounds · 2 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series D extension | $50M | Prime Radiant Fund SLP SICAV-RAIF — Participant | |
| Series D | $257M | Baillie Gifford — Role not disclosedBlackRock — Role not disclosedDC Global Ventures — Role not disclosedDFJ Growth — Role not disclosedDuquesne Family Office — Role not disclosedEclipse — Role not disclosedEDBI — Role not disclosedGates Frontier — Role not disclosedIntuitive Ventures — Role not disclosedT. Rowe Price Investment Management — Role not disclosedWillett Advisors — Role not disclosed |